Alpha Teknova (TKNO) investor relations material

Executive summary

• Q3 revenue reached a record $12.704M, up 21.5% YoY and marking a second consecutive quarterly record; growth came from life science tools, diagnostics and biopharma customers.

• Management cited early signs of improving biotech funding and expects continued momentum, while noting the recovery remains early-stage.

• Business indicators included 3,000+ active customers, 95% customer retention, 70+ therapies supported and ~24% of revenue from cell and gene therapy.

Financial highlights

• Q3 gross profit was $4.826M vs. $3.206M; operating expenses were $8.032M vs. $7.223M.

• Net loss narrowed to $3.490M, or $0.06 per diluted share, from $4.286M, or $0.08; adjusted EBITDA loss improved to $1.0M from $1.6M.

• Nine-month revenue was $35.966M vs. $30.536M; net loss was $11.215M vs. $12.501M.

• Q3 sales and marketing expense rose 34.4% to $2.3M, primarily on higher headcount; total operating expenses increased 11.2%.

Outlook and guidance

• FY 2026 revenue guidance increased to $46M–$48M, implying 16% YoY growth at the midpoint; free cash outflow is expected below $8M.

• Adjusted EBITDA breakeven is expected at $52M–$57M annualized revenue; a positive adjusted EBITDA quarter is targeted before end-2027, subject to market conditions and commercial investment returns.

• Q4 operating expenses are forecast at least $8M; full-year sales and marketing investment is expected to be ~$2M, and Q4 free cash outflow is expected to be similar to Q3.

• Runway assumptions include average low-double-digit revenue growth, ~70% contribution margin on incremental revenue, limited annual OpEx growth and ~$2M annual capex.

• 2027 revenue guidance will be provided with FY 2026 results; management cited biotech funding tailwinds and customers advancing through clinical phases as growth supports.